Clinical Trial Search

Primary: Number of Participants With Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurements of >2 Logs From Baseline at 12 Weeks of Treatment — 1; 1; 1; 0…

Primary: Number of Participants With Decline of Hepatitis D Virus (HDV) RNA Viral Titer of >2 Logs — 18 Participants

Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03

Primary: Histological Response at 3 Years — 6 participants

Primary: Percentage of Participants With Combined Response at Week 48 — 2.0; 44.9; 48.0 percentage of participants — p=<0.0001

Primary: Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) — 16.7; 32.0; 46.0; 12.0 percentage of…

Primary: Change From Baseline in HDV Viral Load. — -2.14; -1.16 Change in HDV RNA log IU/mL

Primary: Change From Baseline to Week 24 in Mean Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) Titer — -1.62 log IU/mL

Primary: Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72 — 54.84 percentage of participants

Primary: Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment…

Primary: Percentage of Patients With Negative HDV RNA by PCR — 0; 53.3; 26.7; 6.7 Percentage of participants — p=0.0022

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at Post-Treatment Follow-up Week 24 (SVR24) — 91.2 Percentage of participants

Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants

Primary: Double-blind: Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in…

Primary: Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy — 0; 0; 0 Participants

Primary: Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy — 45; 16; 290; 2…

Primary: HDV RNA Response at Week 24 — 15; 16; 23; 1 Participants — p=<.0001

Primary: Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population) — 52 participants

Primary: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 — 6.045 Events per person-year

Primary: Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND) — 90.1…

Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml

Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…

Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants

Primary: Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores — 87.27; 87.33; -1.56; 81.71 score on a scale

Primary: ≥2 log10 Decline of HDV RNA From Baseline at End of Treatment (EOT) — 1; 0; 1; 0 Participants

Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…

Primary: Number of Participants With a Virological Response — 12; 24; 9; 27 Participants

Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294

Primary: Alanine Aminotransferase at Baseline — 109.2; 106.3; 110.6 IU/L

Primary: Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA of All Participants — -2.13; -3.31; -2.91; -2.58 log10 IU/mL